We offer a subscription service with a nightly email, research reports, SMS alerts, education, group chat and more. Click here to see our offerings and plans.
- Nabriva Therapeutics is a commercial-stage biopharmaceutical company that is headquartered in Dublin and focused on developing new antibiotics to treat infectious diseases
- NBRV has an approved product Xenleta which is an antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP)-Is partnered with Sinovant in China
- Lead clinical-stage asset CONTEPO = first-in-class IV antibiotic with the potential to work against Gram-negative and -positive bacteria, including most contemporary MDR strains that threaten hospitalized patients